Once-daily (od), low-dose aspirin (75–100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharmacodynamics in the two settings. However, the pharmacodynamics of low-dose aspirin is impaired in ET, reflecting accelerated renewal of platelet cyclooxygenase (COX)-1. ARES is a parallel-arm, placebo-controlled, randomized, dose-finding, phase II trial enrolling 300 ET patients to address two main questions. First, whether twice or three times 100 mg aspirin daily dosing is superior to the standard od regimen in inhibiting platelet thromboxane (TX)A2 production, without inhibiting vascular prostacyclin biosynthesis. Second, whether long-term persistence of superior biochemical efficacy can be safely maintained with multiple vs. single dosing aspirin regimen. Considering that the primary study end point is serum TXB2, a surrogate biomarker of clinical efficacy, a preliminary exercise of reproducibility and validation of this biomarker across all the 11 participating centers was implemented. The results of this preliminary phase demonstrate the importance of controlling reproducibility of biomarkers in multicenter trials and the feasibility of using serum TXB2 as a reliable end point for dose-finding studies of novel aspirin regimens.

De Stefano, V., Rocca, B., Tosetto, A., Soldati, D., Petrucci, G., Beggiato, E., Bertozzi, I., Betti, S., Carli, G., Carpenedo, M., Cattaneo, D., Cavalca, V., Dragani, A., Elli, E., Finazzi, G., Iurlo, A., Lanzarone, G., Lissandrini, L., Palandri, F., Paoli, C., Rambaldi, A., Ranalli, P., Randi, M., Ricco, A., Rossi, E., Ruggeri, M., Specchia, G., Timillero, A., Turnu, L., Vianelli, N., Vannucchi, A., Rodeghiero, F., Patrono, C., The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting, <<BLOOD CANCER JOURNAL>>, 2018; 8 (6): 49-N/A. [doi:10.1038/s41408-018-0078-3] [http://hdl.handle.net/10807/122391]

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

De Stefano, Valerio
Membro del Collaboration Group
;
Rocca, Bianca
Membro del Collaboration Group
;
Soldati, Denise
Membro del Collaboration Group
;
Petrucci, Giovanna
Membro del Collaboration Group
;
Betti, Silvia
Membro del Collaboration Group
;
Ranalli, Paola
Membro del Collaboration Group
;
Rossi, Elena
Membro del Collaboration Group
;
Patrono, Carlo
Membro del Collaboration Group
2018

Abstract

Once-daily (od), low-dose aspirin (75–100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharmacodynamics in the two settings. However, the pharmacodynamics of low-dose aspirin is impaired in ET, reflecting accelerated renewal of platelet cyclooxygenase (COX)-1. ARES is a parallel-arm, placebo-controlled, randomized, dose-finding, phase II trial enrolling 300 ET patients to address two main questions. First, whether twice or three times 100 mg aspirin daily dosing is superior to the standard od regimen in inhibiting platelet thromboxane (TX)A2 production, without inhibiting vascular prostacyclin biosynthesis. Second, whether long-term persistence of superior biochemical efficacy can be safely maintained with multiple vs. single dosing aspirin regimen. Considering that the primary study end point is serum TXB2, a surrogate biomarker of clinical efficacy, a preliminary exercise of reproducibility and validation of this biomarker across all the 11 participating centers was implemented. The results of this preliminary phase demonstrate the importance of controlling reproducibility of biomarkers in multicenter trials and the feasibility of using serum TXB2 as a reliable end point for dose-finding studies of novel aspirin regimens.
2018
Inglese
De Stefano, V., Rocca, B., Tosetto, A., Soldati, D., Petrucci, G., Beggiato, E., Bertozzi, I., Betti, S., Carli, G., Carpenedo, M., Cattaneo, D., Cavalca, V., Dragani, A., Elli, E., Finazzi, G., Iurlo, A., Lanzarone, G., Lissandrini, L., Palandri, F., Paoli, C., Rambaldi, A., Ranalli, P., Randi, M., Ricco, A., Rossi, E., Ruggeri, M., Specchia, G., Timillero, A., Turnu, L., Vianelli, N., Vannucchi, A., Rodeghiero, F., Patrono, C., The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting, <<BLOOD CANCER JOURNAL>>, 2018; 8 (6): 49-N/A. [doi:10.1038/s41408-018-0078-3] [http://hdl.handle.net/10807/122391]
File in questo prodotto:
File Dimensione Formato  
DE stefano et al ET2018.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 525.58 kB
Formato Adobe PDF
525.58 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/122391
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 27
social impact